加载中
NASDAQHealthcareBiotechnology
最新数据
US$139.13
−US$1.79 · -1.27%
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
常规交易时段
US$139
−US$1.9194 · -1.36%
盘中时间采用ET。市场数据可能有所延迟。
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
日内区间
当前US$139
52周区间
当前US$139
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
2
估值过高
情绪
59
多空交织
风险
46
风险偏高
动量
80
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
日内区间
当前US$139
52周区间
当前US$139
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4601.6万 USD | 4.34亿 USD | 6000万 USD | 2658.1万 USD | 2735.7万 USD |
| 销货成本 | 122.5万 USD | — | — | — | — |
| 毛利 | 4479.1万 USD | 4.34亿 USD | 6000万 USD | 2658.1万 USD | 2735.7万 USD |
| 研究与开发 | 1.59亿 USD | 1.38亿 USD | 1.2亿 USD | 1.26亿 USD | 1.26亿 USD |
| 销售、一般及管理费用 | 4485.3万 USD | 4346.2万 USD | 3349.1万 USD | 3173.9万 USD | 2719.6万 USD |
| 营业费用 | 2.03亿 USD | 1.82亿 USD | 1.54亿 USD | 1.58亿 USD | 1.53亿 USD |
| 利息收入 | 2878.9万 USD | 2631.5万 USD | 1489.8万 USD | 406万 USD | 44.3万 USD |
| 折旧和摊销 | 128万 USD | 296.3万 USD | 331.2万 USD | 336.9万 USD | 277.5万 USD |
| 营业利润 | −1.58亿 USD | 2.53亿 USD | −9365.2万 USD | −1.31亿 USD | −1.26亿 USD |
| 净利润 | −1.3亿 USD | 2.75亿 USD | −7895.5万 USD | −1.27亿 USD | −1.26亿 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$176.29
上涨空间 26.83%报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR5.45亿0.53%1042.94亿 USD0.06%US$136.55-0.39%
Vanguard Morningstar Total Stock Market ETFVTI3.03亿0.01%2.3万亿 USD0.03%US$380.19-0.22%
iShares Russell 2000 ETFIWM2.28亿0.29%785.63亿 USD0.19%US$276.04-0.60%
Vanguard Morningstar Small-Cap ETFVB2.19亿0.12%1853亿 USD0.03%US$286.1-0.31%
State Street SPDR S&P Biotech ETFXBI1.47亿1.46%100.75亿 USD0.35%US$146.86-2.25%
Vanguard Morningstar Small-Cap Growth ETFVBK1.25亿0.27%447亿 USD0.05%US$339.73-0.73%
Vanguard Extended Market ETFVXF1.04亿0.11%954亿 USD0.05%US$232.35-0.49%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM8488.6万0.53%160.11亿 USD0.03%US$53.08-0.38%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
